---

Study Model: Intrathecal Dexmedetomidine in LSCS with Nipping/Pinching Test

---

1. DRUG PROFILE - Dexmedetomidine (Dexmed)

Miller's Anesthesia 10e, p. 6062

---

2. STUDY DESIGN FRAMEWORK

Study Title (suggested)

Patient Population

• Inclusion: ASA I-II parturients, singleton term pregnancy, elective/emergency LSCS, age 18-40 years, weight 50-90 kg, spinal anesthesia planned
• Exclusion: Contraindications to spinal (coagulopathy, infection at site, patient refusal), severe cardiac disease, pre-existing neurological disease, allergy to study drugs, fetal distress requiring immediate GA, BMI >40

Groups (3-arm parallel RCT)

---

3. NIPPING/PINCHING TEST - Block Assessment

How to Perform

1. After intrathecal injection, position patient supine with left lateral tilt (15°)
2. Begin testing 2 minutes after injection, repeat every 2 minutes
3. Use a toothed forceps (Allis/tissue forceps) or fingernail pinch - nip the skin firmly
4. Test bilaterally in a dermatomal pattern - start from foot, move cephalad
5. Patient reports "sharp" (pain felt = block incomplete) or "dull/pressure" (block achieved)
6. Target level for LSCS = T4-T6 (nipple line or above)

Dermatomal Landmarks for Pinching Test

Block Assessment Protocol (Bromage Scale for Motor + Pinch for Sensory)

• Sensory block onset time: Time from injection to loss of pinprick/nipping sensation at T10
• Time to achieve T4 block: Documented in minutes
• Maximum sensory level: Highest dermatomal level where nipping is perceived as dull
• Sensory block regression: Time for 2-dermatomal regression from maximum level
• Complete sensory recovery: Return of normal pinprick sensation at S1

---

4. PRIMARY AND SECONDARY OUTCOMES

Primary Outcomes

1. Duration of sensory block - Time from injection to two-dermatomal regression (from max block level)
2. Time to first analgesic request (minutes)

Secondary Outcomes

---

5. WHAT TO EXPECT - EVIDENCE SUMMARY

Block Characteristics

Side Effect Profile (Dexmed vs Fentanyl)

Neonatal Safety

• No significant difference in APGAR scores at 1 and 5 minutes
• No adverse neonatal outcomes documented in current evidence
• Considered safe at doses 5-10 mcg intrathecally

Network meta-analysis by Ollosu et al. (Reg Anesth Pain Med 2026) - 166 RCTs, 14,925 patients - confirms dexmedetomidine significantly prolongs motor block duration; safety profile adequate.

---

6. MECHANISM - HOW IT WORKS INTRATHECALLY

Intrathecal Dexmedetomidine
         ↓
Binds α2 receptors in Dorsal Horn (Substantia Gelatinosa)
         ↓
   ┌─────────────────────────────┐
   │ Presynaptic                 │  Reduces neurotransmitter 
   │ (Primary afferent terminal) │  release (substance P, glutamate)
   └─────────────────────────────┘
         +
   ┌─────────────────────────────┐
   │ Postsynaptic                │  Hyperpolarization → blocks 
   │ (Dorsal horn neuron)        │  pain pulse transmission
   └─────────────────────────────┘
         ↓
   Prolonged sensory + motor blockade
   Anti-shivering effect (thermoregulatory center in locus coeruleus)
   Sedation (locus coeruleus α2 receptors)

---

7. STUDY METHODOLOGY SNAPSHOT

---

8. TYPICAL OBSERVATION TABLE FOR YOUR STUDY

---

9. STATISTICAL ANALYSIS PLAN

---

10. KEY REFERENCES

1. Giaccari LG et al. - Systematic Review & Meta-Analysis, 2024. Eur Rev Med Pharmacol Sci - Bupivacaine + Dex vs Bupivacaine alone in CS (PMID 39194198)
2. Boshoff J et al. - JBI Systematic Review, 2025. Dexmed vs fentanyl in CS (PMID 41185983)
3. Ollosu M et al. - Network Meta-Analysis, Reg Anesth Pain Med 2026. All intrathecal adjuvants in CS (PMID 40147822)
4. Huda AU et al. - Meta-Analysis, JCPSP 2026. IT Dex vs Fentanyl in LSCS (PMID 42219838)
5. Miller's Anesthesia 10e, Chapter 41 - Spinal Anesthesia, pp. 6062-6063
6. Barash Clinical Anesthesia 9e, Chapter 35 - Adjuvants, p. 2843

---

QUICK RECALL BOX

"Dexmed IT in LSCS"

• Dose: 5-10 mcg
• Drug: Preservative-free, diluted in CSF
• Block: Faster onset, longer sensory + motor duration
• Analgesia: +~90 min longer than fentanyl
• Wins vs opioids: No pruritus, less shivering, less PONV
• Watch for: Bradycardia (2%), Hypotension (2%)
• Neonates: SAFE - APGAR scores unaffected
• Nipping test target: T4 (nipple line) before skin incision

---

---

Study Model: Intrathecal Dexmedetomidine vs Fentanyl in LSCS with Nipping Test

---

1. DRUG PROFILES - HEAD TO HEAD

---

2. STUDY DESIGN

Title

Groups (2-arm RCT)

Both groups receive the same volume. Drug preparation by a non-blinded assistant anesthesiologist. Assessor and patient remain blinded.

---

3. NIPPING TEST PROTOCOL (Block Assessment)

Sensory Block Testing

• Use toothed tissue forceps (Allis forceps) or fingernail pinch
• Test every 2 minutes after injection
• Test bilaterally, cephalad direction from foot
• Patient scores sensation as: Sharp (0) = block absent / Dull (1) = block present
• Minimum required level before skin incision = T4 (nipple line)

Dermatomal Map for Nipping Test

T4  → Nipple line          ← TARGET for LSCS
T6  → Xiphoid process
T8  → Costal margin
T10 → Umbilicus            ← Earliest clinically meaningful level
T12 → Inguinal ligament
L1  → Groin
S1  → Lateral foot

Block Parameters Recorded

---

4. PRIMARY + SECONDARY OUTCOMES

Primary Outcomes

1. Duration of effective analgesia (min) - injection to first rescue analgesic request
2. Duration of sensory block (min) - injection to two-dermatomal regression

Secondary Outcomes

---

5. EXPECTED RESULTS - EVIDENCE-BASED COMPARISON TABLE

From Boshoff et al. JBI Systematic Review 2025 (PMID 41185983) - 15 studies, 1098 patients, GRADE evidence:

From Huda & Minhas Meta-Analysis JCPSP 2026 (PMID 42219838) - specifically in LSCS:

---

6. MECHANISM COMPARISON DIAGRAM

INTRATHECAL FENTANYL                    INTRATHECAL DEXMEDETOMIDINE
        ↓                                           ↓
Binds μ-opioid receptors              Binds α2-adrenergic receptors
in dorsal horn                         in dorsal horn
        ↓                                           ↓
Inhibits substance P release          Presynaptic: ↓ neurotransmitter release
Reduces Ca²⁺ influx                   Postsynaptic: Hyperpolarization
Opens K⁺ channels                     (K⁺ channel activation)
        ↓                                           ↓
Rapid onset (lipophilic)              Moderately fast onset
Short-medium duration                 LONGER duration
        ↓                                           ↓
SIDE EFFECTS:                         SIDE EFFECTS:
• Pruritus (most common)              • Bradycardia (mild)
• Nausea/Vomiting                     • Hypotension (mild)
• Respiratory depression (rare)       • Sedation
• Shivering                           ✓ No pruritus
• Urinary retention                   ✓ Less shivering
                                      ✓ Less PONV
                                      ✓ Neonatal safe

---

7. SIDE EFFECT COMPARISON - CLINICAL IMPORTANCE IN OBSTETRICS

---

8. OBSERVATION CHART TEMPLATE

---

9. WHY CHOOSE DEXMED OVER FENTANYL IN LSCS - SUMMARY

Advantages of Dexmed

1. Longer analgesia - ~82-93 min more than fentanyl (avoids early postop pain)
2. Anti-shivering - direct effect on locus coeruleus thermoregulatory centers - extremely valuable in awake LSCS patients
3. No pruritus - fentanyl's #1 complaint; dexmed has 11% absolute risk reduction
4. Less PONV - 7% absolute risk reduction
5. Opioid-sparing - reduces postoperative opioid requirement
6. Neonatal safety - APGAR scores unaffected
7. Faster onset - quicker to achieve T4 level on nipping test

Disadvantages / Cautions

1. Bradycardia risk (mild, ~2% increase) - have atropine ready
2. Hypotension (mild, ~2% increase) - have vasopressor ready
3. Prolonged motor block - may delay ambulation slightly
4. Optimal dose not yet fully standardized (5 vs 10 mcg debated)
5. Less accumulated long-term safety data vs fentanyl

---

10. QUICK RECALL CARD

┌────────────────────────────────────────────────────────────────────┐
│          DEXMED vs FENTANYL — INTRATHECAL in LSCS                 │
├─────────────────────┬─────────────────────┬───────────────────────┤
│ Parameter           │ Dexmed (5 mcg)      │ Fentanyl (25 mcg)     │
├─────────────────────┼─────────────────────┼───────────────────────┤
│ Onset               │ FASTER              │ Fast                  │
│ Sensory duration    │ LONGER              │ Shorter               │
│ Analgesia duration  │ +82-93 min more     │ Baseline              │
│ Nipping test T4     │ Achieved faster     │ Achieved              │
│ Motor block         │ Prolonged slightly  │ Shorter               │
│ Pruritus            │ RARE                │ 30-50%                │
│ Shivering           │ LESS                │ Common                │
│ PONV                │ LESS                │ Common                │
│ Bradycardia         │ Monitor (2% more)   │ Rare                  │
│ Hypotension         │ Monitor (2% more)   │ Rare                  │
│ Neonatal safety     │ SAFE                │ SAFE                  │
└─────────────────────┴─────────────────────┴───────────────────────┘
VERDICT: Dexmed SUPERIOR for quality of block + side effect profile
         in awake LSCS patients

---

KEY REFERENCES

1. Boshoff J et al. JBI Evid Synth 2025 - Dexmed vs Fentanyl systematic review, 15 studies, 1098 patients (PMID 41185983)
2. Huda AU & Minhas MR. J Coll Physicians Surg Pak 2026 - Meta-analysis in LSCS specifically (PMID 42219838)
3. Giaccari LG et al. Eur Rev Med Pharmacol Sci 2024 - Dexmed vs Bupivacaine alone, 14 RCTs (PMID 39194198)
4. Ollosu M et al. Reg Anesth Pain Med 2026 - Network meta-analysis, 166 RCTs, all adjuvants (PMID 40147822)
5. Miller's Anesthesia 10e, pp. 6062-6063 - α2-Agonists as intrathecal adjuvants
6. Barash Clinical Anesthesia 9e, p. 2843 - Subarachnoid adjuvants